Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CDC25B | P30305 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19616584 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP2A6NQO1MAPTCDC25B | |
| SCHEMBL5782272 | 0.82 | CYP1A2 (0.54) | CYP1A2CYP2A6NQO1MAPTCDC25B | |
| SCHEMBL30011882 | 0.82 | CYP1A2 (0.54) | CYP1A2CYP2A6NQO1MAPTCDC25B | |
| SCHEMBL29843404 | 0.82 | SLC9A1 (0.36) | CYP1A2CYP2A6MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL19637220 | 0.81 | CYP1A2 (0.48) | CYP1A2CYP2A6NQO1MAPTCDC25B | |
| SCHEMBL23043017 | 0.80 | NQO2 (0.52) | CYP1A2CYP2A6NQO1CDC25BGRM5 | |
| SCHEMBL19616662 | 0.80 | CYP1A2 (0.36) | CYP1A2CYP2A6NQO1MAPTCDC25B | |
| SCHEMBL30391379 | 0.80 | NQO2 (0.52) | CYP1A2CYP2A6NQO1CDC25BGRM5 | |
| SCHEMBL30064821 | 0.80 | CYP1A2 (0.36) | CYP1A2CYP2A6NQO1MAPTCDC25B | |
| SCHEMBL23409334 | 0.79 | CYP1A2 (0.35) | CYP1A2CYP2A6NQO1MAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| EP-4581024-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2025-07-09 | — | — | EP | disclosed |
| CN-119855815-A | KRAS mutant protein inhibitor, and preparation method and application thereof | 甘李药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| CN-115003677-B | Compounds having inhibitory activity against KRAS G12D mutations | 大鹏药品工业株式会社 | 2024-08-27 | — | — | CN | disclosed |
| CN-118434748-A | Six-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2024-08-02 | — | — | CN | disclosed |
| WO-2024115890-A1 | COMPOUNDS | REDX PHARMA PLC (GB) | 2024-06-06 | — | — | WO | disclosed |
| EP-4352061-A1 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS | Redx Pharma Plc (GB) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347589-A2 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS CAPABLE OF INHIBITING KRAS MUTANT PROTEINS | Redx Pharma Plc (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024047135-A1 | SUBSTITUTED HETEROCYCLES AS RAS INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-03-07 | — | — | WO | disclosed |
| CN-117466917-A | Heterocyclic derivative, preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117460730-A | Pyrido [4,3-D ] pyrimidine compounds capable of inhibiting KRAS muteins | 莱德克斯制药公共有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117425658-A | Quinazoline derivatives as RAS inhibitors | 莱德克斯制药公共有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-116891488-A | Condensed-cyclic compound, pharmaceutical composition containing condensed-cyclic compound and application of condensed-cyclic compound | 成都海博为药业有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022258974-A1 | QUINAZOLINE DERIVATIVES USEFUL AS RAS INHIBITIORS | REDX PHARMA PLC (GB) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022248885-A2 | COMPOUNDS | REDX PHARMA PLC. (GB) | 2022-12-01 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |